Research Article

Postoperative Ileus with the Topical Application of Tongfu Decoction Based on Network Pharmacology and Experimental Validation

Ximeng Zuo,1 Xiaoguang Shi,1 Xuedan Zhang,2 Zhenzhou Chen,1 Zhenrui Yang,1 Xiaojuan Pan,1 Rui Lai,1 and Ze Zhao1

1Department of General Surgery, Beijing University of Chinese Medicine Dongzhimen, No. 5 Shipping Warehouse, Dongcheng District, Beijing 100700, China
2Department of Chinese Medicine, Beijing Daxing District People’s Hospital, 26 Huangcun West Street, Daxing District, Beijing, China

Correspondence should be addressed to Zhenzhou Chen; chenzhenzhou6@gmail.com

Received 4 November 2021; Revised 20 February 2022; Accepted 14 March 2022; Published 28 March 2022

Academic Editor: Talha Bin Emran

Copyright © 2022 Ximeng Zuo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Postoperative gastrointestinal dysfunction is a common and important complication of surgery. This study aimed to explore the key pharmacological mechanisms of Tongfu decoction in treating postoperative ileus (POI). Methods. The active ingredients of Tongfu decoction and their targets were screened using the TCMSP database and STITCH and SwissTargetPrediction databases, respectively. The GeneCards and DisGeNET databases were used to obtain POI dysfunction-related therapeutic targets. After screening, a drug-active-ingredient-therapeutic target network was constructed and the key target functional enrichment analysis was carried out. The Sprague–Dawley rats with POI were used for in vivo experimental verification. The serum levels of IL-1β, IL-6, IL-10, IFN-γ, and MCP-1 were measured after surgery using enzyme-linked immunosorbent assay. The Western blot analysis was used to determine the expression of key proteins of the PI3K-Akt signaling pathway in colon tissues. Results. An interaction network was constructed containing 7 Chinese medicine components, 36 compounds, and 85 target proteins. The functional enrichment analysis showed that the target proteins mainly acted on the POI through the PI3K-Akt signaling pathway. In vivo experiments, Tongfu decoction had a promoting effect on the serum level of IL-10, an inhibitory effect on the serum levels of IL-1β and CCL2, and an inhibitory effect on the local expression of PI3K, pAkt, and mTOR in colon tissue. In addition, the Tongfu decoction increased the intestinal ink advancing rate. Conclusion. Nonoral Tongfu decoction can also be used to treat POI; its mechanism is affected by IL-10 and IL-1β. The inhibition of the PI3K-Akt signaling pathway affected the treatment with Tongfu decoction by inducing an immune-inflammatory storm in POI.

1. Introduction

In this study, the key pharmacological mechanism of Tongfu decoction, a traditional Chinese medicine (TCM), in treating postoperative gastrointestinal dysfunction was mainly explored through network pharmacology and experimental verification. Postoperative ileus (POI) is one of the major postoperative complications of gastrointestinal surgery. Its etiology has been mainly classified into two stages. The early stage is 3–6 h after surgery, during which sympathetic inhibition is induced by surgical stimulation. The second stage is 6–72 h after surgery, during which an immune mediator-driven inflammation occurs [1]. If the patient is unable to recover within 120 h, these complications may lead to more serious consequences [2] and even death.

At present, the main way to prevent and treat POI is the promotion of enhanced recovery surgery (ERAS). ERAS was proposed by Kehlet in the 1990s, and it has been continuously optimized and improved. ERAS is a multidisciplinary, individualized diagnosis and treatment discipline involving a team of surgeons, anesthesiologists, and nursing staff. Its main purpose is to speed up the postoperative rehabilitation
process and reduce the incidence of postoperative complications [3]. The content of ERAS in modern medicine includes fasting for 2 h before surgery, application of minimally invasive surgery, improvement in anesthesia plan, liquid management of postoperative parenteral nutrition, reasonable drainage tube removal, and preoperative and postoperative missions [4]. The main purpose of this treatment is to shorten the length of hospitalization and reduce the cost of hospitalization and incidence of postoperative complications, but the problem of poor compliance still exists.

In previous studies, TCM promoted the recovery of patients [5–11] and had a synergistic effect on ERAS [12–15]. One of the drugs used was Tongfu decoction, having a certain effect on POI using nonoral treatment methods such as rectal instillation, which could accelerate the recovery of postoperative gastrointestinal function and relieve postoperative inflammation of the digestive tract [16–19]. The theory of TCM believes that the treatment of Tongli Gongxia, which lowers the adversity and regulates qi, can relieve abdominal distension, nausea, and vomiting in patients with POI. Also, it promotes postoperative defecation and inhibits inflammation [20]. Despite some promising clinical evidence, the pharmacological mechanism of Tongfu decoction in treating POI remains unexplored.

2 Methods

2.1 Network Pharmacology

2.1.1 Screening of Active Compounds in Compound Prescriptions. The TCMSP database, which is a pharmacological database and analysis platform of the Chinese medicine system (http://lsp.nwu.edu.cn/tcmsp.php), was used in this study. The database included 499 Chinese medicines registered in the Chinese Pharmacopoeia, containing 29,384 ingredients, 3311 targets, and 837 related diseases. The disease information in this database comes from the TTD and PharmGKB databases. The active ingredients of Rhubarb, Magnolia officinalis, Fructus Aurantii, Angelica sinensis, Toosendan Fructus, and Aucklandiae Radix were searched in the TCMSP database using OB and DL as indicators, ADME as a comprehensive model, and oral bioavailability of OB ≥ 30% and drug similarity DL ≥ 0.18 as screening thresholds.

2.1.2 Screening of Active Compound Targets. STITCH (https://stitch.embl.de/) and SwissTargetPrediction databases were used to screen the targets of active compounds of Tongfu decoction obtained in Section 2.1.1. The PubChem database (https://pubchem.ncbi.nlm.nih.gov/) was used to add all the active compounds to the STITCH database. The compound was converted into the standard canonical SMILES format and imported into SwissTargetPrediction. The target with parameter probability >0 was selected for further analysis.

2.1.3 Construction of Pharmacologically Active Compound-Target Protein Network. Based on the results of the target proteins of the pharmacologically active compounds screened using STITCH and SwissTargetPrediction, Cytoscape was used to construct the “pharmacologically active compound-target protein network” in the compound.

2.1.4 Screening for Targets of POI. GeneCards (https://www.drugbank.ca/) and DisGeNET (https://www.disgenet.org/) were used to uncover the genes that affected POI. The intersection targets of genes that affected POI and the target protein of the compound with drug activity were the key research objects.

2.1.5 Constructing Key Target PPI Networks. A key target PPI network was constructed using the STRING (https://stringdb.org) website to understand the functions and connections of the aforementioned proteins. Cytoscape completed the drawing and beautification of the network.

2.1.6 GO and KEGG Enrichment Analyses. GO enrichment and KEGG analyses on the intersection genes were conducted in the R software clusterProfiler package. Pathview was used to visualize the KEGG pathway. GO enrichment analysis mainly described the biological processes (BP), cellular components (CC), and molecular functions (MF) correlated with genes.

2.2 Experiment

2.2.1 Composition of Tongfu Decoction. The external preparation of Tongfu decoction comprised Chinese medicine decoction pieces. These pieces were selected by Beijing Tongrentang Pharmaceuticals. The specific ingredients were as follows: Rhubarb, M. officinalis, Fructus Aurantii, A. sinensis, radish seeds, Toosendan Fructus, and Aucklandiae Radix. The aforementioned drug was crushed and mixed with petroleum jelly. The weight ratio of drug:petroleum jelly was 1:2 to make a plaster with a weight of 5 g.

2.2.2 Animal Experiments. The experimental animals were healthy male Sprague–Dawley rats, aged 9–10 weeks, and weighing 200 ± 10 g, which were routinely reared. These rats were divided into model (small intestine surgery) group, negative control (abdominal incisions only) group, Tongfu decoction group, neostigmine group, and blank group. Each group was randomly divided into postoperative 24-h, 72-h, and 120-h groups. The rats in each group were fasted for 24 h before surgery and allowed to drink water ad libitum. The method of modeling was an aseptic operation, which involved opening the abdominal cavity via a midline incision of the abdomen, turning the small intestine to the left, placing it on the gauze soaked with normal saline, and squeezing from the dactyly to the ileocecal area. This step was to simulate the clinically common whole small-bowel explorative surgery. The rats in the negative control group only underwent opening of the abdomen and intestines without pushing operation. Then, the small intestine was returned in order, a small amount of saline was sprinkled...
into the abdominal cavity, and the abdominal cavity was closed with intermittent sutures.

After the surgery, the rats were subcutaneously injected with 20,000 IU/kg penicillin G sodium and 250 mg/kg streptomycin sulfate on the back for three consecutive days. In the neostigmine group, 10 μg of neostigmine mesylate was subcutaneously injected daily. The Tongfu decoction was applied to the scapular skin of the rats in the form of a patch and fixed with tape. The dressing was changed every 24 h. After the surgery, the rats were fasted for 48 h without water and given 20% glucose solution twice in the morning and evening at an interval of 8 h. On the third day after the surgery, 20 mL/kg feed paste was fed (standard feed was superfinely pulverized, and 20% feed paste was prepared). The diet was provided free on the fourth day.

2.2.4. Statistical Analysis. The mean for the treated experimental and control groups. The Student t-test was used for the data between the two groups. The results were presented as the mean ± standard error of the mean for the treated experimental and control groups. The p values were indicated as *p < 0.05, **p < 0.01, and ***p < 0.001.

3. Results

3.1. Active Ingredients and Targets in Tongfu Decoction. The active ingredients corresponding to Rhubarb, M. officinalis, Fructus Aurantii, A. sinensis, Toosendan Fructus, and Aucklandiae Radix were uncovered by searching in the TCMSP database (Table 1).

3.2. Potential Target of Tongfu Decoction in Treating POI. Based on the results of the target proteins of the pharmacologically active compounds screened by STITCH and SwissTargetPrediction, Cytoscape was used to construct a compound with pharmacological activity-target protein network, which contained 39 compounds and corresponding 649 target proteins (Figure 1(a)).

Then, the genes that affected POI were screened using GeneCards and DisGeNET, and the interaction with the target protein of the drug-active compound in Figure 1 was taken, obtaining 85 overlapping genes (Figure 2(a)).

3.3. PPI Network Establishment. A PPI network based on 85 intersection genes was created using the STRING website (Figure 2(b)). Cytoscape was used to complete network drawing and beautification (Figure 2(c)). A drug-active ingredient-target protein network was further established (Figure 2(c)).

3.4. GO and KEGG Enrichment Analysis. GO enrichment analysis was performed on 85 intersection genes, and the most significantly enriched 10 GO terms in BP, CC, and MF categories were revealed, as shown in Figure 3(a). The top 5 GO BP terms were "response to drug," "response to lipopolysaccharide," "response to molecule of bacterial origin," "response to oxidative stress," and "cellular response to chemical stress." KEGG enrichment analysis was also performed on the intersection genes, and the 30 most significant signaling pathways were identified, as listed in Figure 3(b). The parts closely related to inflammation were screened. Among these, the PI3K-Akt signaling pathway was significant for POI (Figures 3(b) and 3(c)).

3.5. Effect of Tongfu Decoction on the Intestinal Function of Rats with POI. The pass rate of the intestine for rats with POI was measured to verify the therapeutic effect of Tongfu decoction on POI. The intestine passage rate was significantly higher in rats using Tongfu decoction than in those in the model and neostigmine groups on the third day after the surgery (p < 0.01), suggesting that Tongfu decoction had a certain effect on POI treatment (Figures 4(a) and 4(b)).

The rat colon tissue was HE stained. Rats using Tongfu decoction had a much more complete colonic mucosal epithelial structure and less infiltration of eosinophils, neutrophils, and lymphocytes in colon villi and muscle tissues. Also, they were less prone to vasodilation (Figure 4). These results showed that Tongfu decoction improved the inflammatory pathological changes that occurred after the surgery of the colon tissue in rats.

The rats using Tongfu decoction exhibited a significant increase in the serum level of IL-10 on the first day after the surgery (p < 0.01) and a significant decrease in the serum levels of CCL2 and IL-1β on the fifth day (p < 0.01) (Figure 5).

The expression levels of PI3K, pAkt, and mTOR in the colon tissue of rats treated with Tongfu decoction reduced compared with those in the model group (p < 0.05) (Figure 6).
| Mol ID    | Molecule name                                                  | OB (%) | Caco-2 | DL     | Herb         |
|-----------|---------------------------------------------------------------|--------|--------|--------|---------------|
| MOL002235 | EUPATIN                                                        | 50.8   | 0.53   | 0.41   | Dahuang       |
| MOL002251 | Mutatochrome                                                  | 48.64  | 1.97   | 0.61   | Dahuang       |
| MOL002259 | Physcionidiglucoside                                          | 41.65  | 2.64   | 0.63   | Dahuang       |
| MOL002260 | Procyanidin B-5,3'-O-gallate                                   | 31.99  | 3.05   | 0.32   | Dahuang       |
| MOL002268 | Rhein                                                         | 47.07  | 0.2    | 0.32   | Dahuang       |
| MOL002276 | Sennoside E_qt                                                | 50.69  | 0.74   | 0.61   | Dahuang       |
| MOL002280 | Torachrysone-8-O-beta-D-(6'-oxayl)-glucoside                  | 43.02  | 3.32   | 0.8    | Dahuang       |
| MOL002281 | Toralactone                                                   | 46.46  | 0.86   | 0.24   | Dahuang       |
| MOL002288 | Emodin-1-O-beta-D-glucopyranoside                              | 44.81  | 1.12   | 0.8    | Dahuang       |
| MOL002293 | Sennoside D_qt                                                | 61.06  | 0.7    | 0.61   | Dahuang       |
| MOL002297 | Daucosterol_qt                                                | 35.89  | 1.35   | 0.7    | Dahuang       |
| MOL002303 | Palminid A                                                    | 32.45  | 0.36   | 0.65   | Dahuang       |
| MOL000358 | Beta-sitoster                                                  | 36.91  | 1.32   | 0.75   | Dahuang       |
| MOL000471 | Aloe-emodin                                                   | 83.38  | 0.12   | 0.24   | Dahuang       |
| MOL000554 | Gallic acid-3-O-(6'-O-galloyl)-glucoside                       | 30.25  | 1.96   | 0.67   | Dahuang       |
| MOL000096 | (-)-Catechin                                                  | 49.68  | 0.03   | 0.24   | Dahuang       |
| MOL000570 | Eucalyptol                                                    | 60.62  | 1.1    | 0.32   | Houpu         |
| MOL000590 | Neohesperidin                                                 | 57.44  | 0.29   | 0.27   | Houpu         |
| MOL013276 | Poncicin                                                      | 36.55  | 1.67   | 0.74   | Zhishi        |
| MOL013277 | Isoisinensetin                                                | 51.15  | 1.16   | 0.44   | Zhishi        |
| MOL013279 | 5,7,4'-Trimethylalpinigen                                     | 39.83  | 1.01   | 0.3    | Zhishi        |
| MOL013428 | Isosakuranetin-7-rutinoside                                    | 41.24  | 1.59   | 0.72   | Zhishi        |
| MOL013430 | Prangenin                                                     | 43.6   | 0.8    | 0.29   | Zhishi        |
| MOL013433 | Prangenin hydrate                                             | 72.63  | 0.14   | 0.29   | Zhishi        |
| MOL013435 | Poncimarin                                                    | 63.62  | 0.66   | 0.35   | Zhishi        |
| MOL013436 | Isoponcimarin                                                 | 63.28  | 0.5    | 0.31   | Zhishi        |
| MOL013437 | 6-Methoxy aurapten                                            | 31.24  | 1.01   | 0.3    | Zhishi        |
| MOL013440 | Citrusin B                                                    | 40.8   | 1.94   | 0.71   | Zhishi        |
| MOL0001798| Neohesperidin_qt                                              | 71.17  | 0.26   | 0.27   | Zhishi        |
| MOL0001803| Sinensetin                                                    | 50.56  | 1.12   | 0.45   | Zhishi        |
| MOL0001941| Ammidin                                                       | 34.55  | 1.13   | 0.22   | Zhishi        |
| MOL013352 | Obacunone                                                     | 43.29  | 0.01   | 0.77   | Zhishi        |
| MOL000294 | Eriodictiol (flavanone)                                       | 41.35  | 0.05   | 0.24   | Zhishi        |
| MOL0004328| Naringenine                                                   | 59.29  | 0.28   | 0.21   | Zhishi        |
| MOL0005100| 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one      | 47.74  | 0.28   | 0.27   | Zhishi        |
| MOL0005828| Nobiletin                                                     | 61.67  | 1.05   | 0.52   | Zhishi        |
| MOL0005849| Didymin                                                       | 38.55  | 0.6    | 0.24   | Zhishi        |
| MOL000006 | Luteolin                                                      | 36.16  | 0.19   | 0.25   | Zhishi        |
| MOL0007879| Tetramethoxyluteolin                                          | 43.68  | 0.96   | 0.37   | Zhishi        |
| MOL0009053| 4-[(2S,3R)-5-[(E)-3-Hydroxyprop-1-enyl]-7-methoxy-3-methylol-2,3-dihydrobenzofuran-2-yl]-2-methoxy-phenol | 50.76  | 0.03   | 0.39   | Zhishi        |
| MOL0003358| Beta-sitoster                                                  | 36.91  | 1.32   | 0.75   | Danggui       |
| MOL000449 | Stigmastanol                                                  | 43.83  | 1.44   | 0.76   | Danggui       |
| MOL010672 | Icosa-8,11,14-trienoic acid methyl ester                      | 44.81  | 1.49   | 0.23   | Laifuzi       |
| MOL000359 | Sitosterol                                                    | 36.91  | 1.32   | 0.75   | Laifuzi       |
| MOL000975 | Icosa-11,14,17-trienoic acid methyl ester                     | 44.81  | 1.52   | 0.23   | Laifuzi       |
| MOL001494 | Mandenol                                                      | 42     | 1.46   | 0.19   | Chuanlianzhi  |
| MOL001495 | Ethyl linolenate                                              | 46.1   | 1.54   | 0.2    | Chuanlianzhi  |
| MOL002045 | Stigmastanol                                                  | 43.41  | 1.35   | 0.76   | Chuanlianzhi  |
| MOL002047 | Melanone                                                      | 40.73  | 0.46   | 0.81   | Chuanlianzhi  |
| MOL002048 | Nimbolidin D                                                  | 30.38  | 0.28   | 0.53   | Chuanlianzhi  |
| MOL002053 | Nimbolin A                                                    | 32.11  | 0.52   | 0.34   | Chuanlianzhi  |
| MOL002056 | (E)-3-[((2S,3R)-2-(4-Hydroxy-3-methoxyphenyl)-7-methoxy-3-methylol-2,3-dihydrobenzofuran-5-yl)acrolein | 54.74  | 0.22   | 0.4    | Chuanlianzhi  |
| MOL002058 | 40957-99-1                                                    | 57.2   | 0.49   | 0.62   | Chuanlianzhi  |
| MOL000098 | Quercetin                                                     | 46.43  | 0.05   | 0.28   | Chuanlianzhi  |
| MOL010813 | Benzo[a]carbazole                                             | 35.22  | 1.87   | 0.22   | Muxiang       |
4. Discussion

The main components of Tongfu decoction are tannins, anthracene derivatives, stilbene derivatives, phenbutanone, and naphthalene derivatives. These components increase intestinal mucosal motility, inhibit intestinal water absorption, exert anti-inflammatory effects, and reduce cytokine secretion [21–23]. Glauber’s salt is a natural mineral with Na$_2$SO$_4$·10H$_2$O as the main component, which has anti-inflammatory and cathartic effects. The pharmacological effects of other drugs such as *M. officinalis* and *Citrus aurantium* are related to the improvement in intestinal motility.

This study was conducted to investigate the molecular mechanism of Tongfu decoction in treating POI. Based on the predicted targets of network pharmacology, this study focused on the effects of Tongfu decoction on different immune mediators and the PI3K-Akt signaling pathway. Rats with POI were used as experimental materials to explore the antagonistic effect of Tongfu decoction on the inflammatory response of postoperative colon tissue in rats and to verify the prediction results of network pharmacology. In this study, the network pharmacology methods were used to systematically analyze the TCM compounds in Tongfu decoction at the molecular level. A total of 39 potentially active Chinese medicine compounds, 649 target proteins related to postoperative gastrointestinal dysfunction, 85 potential genes, and 30 most relevant signaling pathways were obtained. According to the KEGG analysis, the signaling pathway with the highest correlation was the PI3K-Akt signaling pathway, suggesting that Tongfu...
Figure 2: (a) Venn diagram showing the overlap of the targets of Tongfude decoction and POI. Blue represents Tongfude decoction targets, while yellow represents POI targets. (b) Target protein interaction network. The nodes in the network represent proteins, the lines show the proteins’ functional associations, and the thickness of lines corresponds to the observed association’s confidence level. (c) Drug-active-ingredient-target protein network. The blue triangle represents the drug, the purple triangle represents the active ingredient, and the green circle represents the target protein.

Figure 3: Continued.
decoction might play a role in treating POI by regulating the PI3K-Akt signaling pathway. This pathway was of great significance in the inflammatory response. This conclusion was confirmed in various experiments. In vivo experiments showed that external application of the Tongfu decoction patch after the surgery could increase the passage rate of small intestinal contents in rats. This meant that not only oral administration but also a topical patch of Tongfu decoction could promote the recovery of small intestinal function. Western blot analysis and ELISA revealed that Tongfu decoction treated the disease by affecting the mechanism of the PI3K-Akt signaling pathway. Tongfu decoction also reduced the serum levels of CCL2 and IL-1β, increased the serum level of IL-10 and reduced the infiltration of local eosinophils and monocytes in colon tissue.

Previous studies demonstrated a reduction in the levels of CCL2 and IL-1β and an increase in the level of IL-10 had positive effects on the treatment of POI. CCL2 is one of the key chemokines regulating monocyte/macrophage migration and infiltration. Its reduction can improve inflammation and POI [24]. An inflammatory mediator, IL-1β directly affects the symptoms of POI (gas, defecation, nausea, vomiting, and so on). Its release depends on the number of AIM2 inflammasomes and microorganisms [25]. IL-10 is a potent anti-inflammatory mediator that reduces neutrophil infiltration, cytotoxicity [26], and inflammatory responses induced by intraoperative hemorrhage [27], regardless of sepsis-induced gastrointestinal function [28] or postoperative gastrointestinal dysfunction [29]. The serum levels of IL-10 peaked about 4 h after laparotomy and returned to normal levels within 3 days after the surgery [30]. In this study, the expression of IL-10 increased on the first day after the surgery, while the levels of CCL2 and IL-1β decreased on the third and fifth days after the surgery, suggesting that Tongfu decoction affected the early postoperative inflammatory response. The secretion of anti-inflammatory mediators had an inhibitory effect on the secretion of inflammatory mediators in the long-term intestinal tract.

The PI3K-Akt signaling pathway plays an important role in the inflammatory response. PI3K signaling promotes the inflammatory activity of T cells by phosphorylating the FOXO transcription factor [31]. In POI, an excessive inflammatory response is not required, and Tongfu decoction can reduce the activity of the PI3K-Akt signaling pathway. In BV2, LPS treatment did not affect the relative levels of PI3K and NF-κB p65 expression but significantly increased the relative levels of phosphorylated Akt and NF-κB p65, implying that pAkt overexpression might affect not only downstream inflammatory expression but also the nervous system, thereby inducing postoperative gastrointestinal dysfunction [33]. The factors such as CCL2 and IL-1β were in the PI3K-Akt-related downstream signaling pathway, which was consistent with the hypothesis that the regulation of PI3K-Akt signaling pathway could affect the development of inflammation in postoperative gastrointestinal dysfunction. Therefore, it was presumed that the main target of Tongfu decoction was the PI3K-Akt signaling pathway.

The comprehensive and systematic analysis of drugs-active-ingredients-target proteins in network pharmacology conforms to the holistic concept, and its research concept coincides with the overall concept of TCM syndrome differentiation and treatment. Network pharmacology is often used in the study of TCM components and targets [32–37], especially TCM compound prescriptions. Different chemical components in TCM compounds may have synergistic effects in terms of reducing toxicity. Therefore, the
combination of TCM and network pharmacology bridges the gap between modern medicine and traditional medicine [38]. This study explored the mechanism of Tongfu decoction in treating postoperative gastrointestinal dysfunction and identified a new form of percutaneous topical administration. In previous studies, rectal instillation and jejunal injection were usually chosen for administration [39], which were associated with problems such as poor compliance and further irritation of the digestive tract.

The form of administration described in the present study provided greater compliance and was simpler than rectal instillation [39, 40]. Moreover, transdermal administration did not consider liver toxicity; only local allergic reactions were considered, and it was highly safe. In

Figure 4: (a) Ink advancement rate of the small intestine. (b) HE staining of the colon tissue in different groups. Compared with the model group, rats treated with Tongfu decoction had more complete colonic mucosal epithelial structure and less infiltration of eosinophils, neutrophils, and lymphocytes in colon villi and muscle tissues and were less prone to vasodilation.
Figure 5: Effects of Tongfu decoction on the expression of IL-6, CCL2, and IFN in villi and muscle tissues and IL-10 (days 1, 3, and 5) after surgery (compared with the model group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, and * p < 0.05).
addition, these results suggested that the therapeutic effect of Tongfu decoction on gastrointestinal dysfunction after gastrointestinal surgery was probably exerted via inhibiting the inflammatory storm induced by the PI3K-Akt signaling pathway. The therapeutic mechanism might be the same. The pharmacological effects of the compound may also be applied to other acute abdominal diseases such as severe pancreatitis and acute peritonitis. Also, the indications can be further explored in subsequent studies.

**Data Availability**

The first author should be contacted to request for the data (ravernyflun@outlook.com or +8615202257239).

**Disclosure**

Ximeng Zuo, Xiaoguang Shi and Xuedan Zhang are the co-first author.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

Zhenzhou Chen contributed to the conception of the study; Ximeng Zuo, Zhenrui Yang, Xiaojuan Pan, Ze Zhao, and Rui
Lai performed the experiment; Xuedan Zhang contributed significantly to analysis and manuscript preparation; Ximeng Zuo performed the data analyses and wrote the manuscript; Xiaoguang Shi helped perform the analysis with constructive discussions.

References

[1] M. Lee, P. Vaughan-Shaw, and D. Vimalachandran, “A systematic review and meta-analysis of baseline risk factors for the development of postoperative ileus in patients undergoing gastrointestinal surgery,” *Annals of the Royal College of Surgeons of England*, vol. 102, no. 3, pp. 194–203, 2020.
[2] C. R. Harnsberger, J. A. Maykel, and K. Alavi, “Postoperative ileus,” *Clinics in Colon and Rectal Surgery*, vol. 32, no. 3, pp. 166–170, 2019.
[3] C. Gillis, M. Gill, N. Marlelt et al., “Patients as partners in enhanced recovery after surgery: a qualitative patient-led study,” *BMJ Open*, vol. 7, no. 6, Article ID e17002, 2017.
[4] O. Ljungqvist, M. Scott, and K. C. Fearon, “Enhanced recovery after surgery,” *JAMA Surgery*, vol. 152, no. 3, pp. 292–298, 2017.
[5] K. Mallikarjuna, O. Nasif, A. S. Ali et al., “Phytogenic synthesis of Pd-Ag/rGO nanostuctures using stevia leaf extract for photocatalytic H2 production and antibacterial studies,” *Biomolecules*, vol. 11, no. 2, 2021.
[6] M. A. Freitas, A. Vasconcelos, E. Goncalves, and A. Mukhopadhyay, “Involvement of opioid system and TRPM8/TRPA1 channels in the antinociceptive effect of spirulina platensis,” *Biomolecules*, vol. 11, no. 4, 2021.
[7] O. Goni, M. F. Khan, M. M. Rahman et al., “Pharmacological insights on the antidepressant, anxiolytic and aphrodisiac potentials of aglaonema hockerianum Schott,” *Journal of Ethnopharmacology*, vol. 268, Article ID 113664, 2021.
[8] M. M. Rahman, F. Islam, A. Farvez et al., “Citrus limon L. (lemon) seed extract shows neuro-modulatory activity in an in vivo thioptental-sodium sleep model by reducing the sleep onset and enhancing the sleep duration,” *Journal of Integrative Neuroscience*, vol. 21, no. 1, p. 42, 2022.
[9] L.-X. Cao, Z.-Q. Chen, Z. Jiang et al., “Rapid rehabilitation technique with integrated traditional Chinese and Western medicine promotes postoperative gastrointestinal function recovery,” *World Journal of Gastroenterology*, vol. 26, no. 23, pp. 3271–3282, 2020.
[10] S. Hossain, Z. Urbi, H. Karuniawati et al., “Andrographis paniculata (burm. F.) wall. Ex nees: an updated review of phytochemistry, antimicrobial pharmacology, and clinical safety and efficacy,” *Jewish Life*, vol. 11, no. 4, 2021.
[11] J. Moni, M. Adnan, A. M. Tareq et al., “Therapeutic potentials of syzygium frutoscum fruit (seed) reflected into an array of pharmacological assays and prospective receptors-mediated pathways,” *Jewish Life*, vol. 11, no. 2, 2021.
[12] T. E. Tallei, Fatimawali, N. J. Niode et al., “A comprehensive review of the potential use of green tea polyphenols in the management of COVID-19,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2021, Article ID 7170736, 13 pages, 2021.
[13] T. Wang, Y. Xu, Q. Chen et al., “Metabolomics analysis of laparoscopic surgery combined with wuda granule to promote rapid recovery of patients with colorectal cancer using UPLC/Q-TOF-MS/MS,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 5068268, 18 pages, 2020.
[14] M. N. Uddin Chy, M. Adnan, M. R. Chowdhury et al., “Central and peripheral pain intervention by Ophiopogon rugos leaves: potential underlying mechanisms and insight into the role of pain modulators,” *Journal of Ethnopharmacology*, vol. 276, Article ID 114182, 2021.
[15] J. Fernández, B. Silván, R. Entrialgo-Cadierno et al., “Anti-proliferative and palliative activity of flavonoids in colorectal cancer,” *Biomedicine & Pharmacotherapy*, vol. 143, Article ID 112241, 2021.
[16] V. Martínez, D. A. Iriondo, F. Borrelli, R. Capasso, M. D. Del Castillo, and R. Abalo, “Cannabidiol and other non-psychoactive cannabinoids for prevention and treatment of gastrointestinal disorders: useful nutraceuticals?” *International Journal of Molecular Sciences*, vol. 21, no. 9, 2020.
[17] M. Tian, Q. L. Sun, Z. H. Chen, G. Wang, and Z. G. Ding, “The effect and mechanism of Tongfu decoction injected through jejunum on gastrointestinal function in patients with severe acute pancreatitis,” *Chin Clin Dr*, vol. 46, no. 3, pp. 291–293, 2018.
[18] J. W. Hao, J. Y. Zheng, L. L. Shi, S. Li, L. Kou, and M. Li, “Clinical study of Tongfu Decoction in the treatment of early intestinal paralysis after abdominal surgery,” *Guide of China Medicine*, vol. 12, no. 14, pp. 285–286, 2014.
[19] B. Deng, N. Q. Li, and L. Li, “Clinical observation of self-made Tongfu Decoction in the treatment of gastrointestinal dysfunction after abdominal non-gastrointestinal anastomosis,” *Journal of Intractable Diseases*, vol. 10, no. 9, pp. 699–700, 2011.
[20] X. R. Ni, Z. Z. Chen, C. G. Xing, M. Tian, G. Wang, and Y. P. Yang, “Treatment of 30 cases of early postoperative inflammatory bowel obstruction with Tongfu Decoction,” *Chinese Journal of Integrated Traditional Chinese and Western Medicine Surgery*, vol. 17, no. 5, pp. 501–502, 2011.
[21] L. Li, X. H. Chen, Z. Li et al., “Professor Li Naqing’s clinical experience in treating intestinal obstruction with Tongfu Decoction,” *Modern Chinese Clinical Med*, vol. 25, no. 4, pp. 5–8, 2018.
[22] E. K. Akkol, I. I. Tatli, G. S. Kataporak et al., “Is emodin with anticancer effects completely innocent? Two sides of the coin,” *Journal of Cancer*, vol. 13, no. 11, 2021.
[23] J. Schmidt, B. Stoffels, R. Savanh Chanthaphavong, B. M. Buchholz, A. Nakao, and A. J. Bauer, “Differential molecular and cellular immune mechanisms of postoperative and LPS-induced ileus in mice and rats,” *Cytokine*, vol. 59, no. 1, pp. 49–58, 2012.
[24] U. Farooq, T. Khan, and S. A. Shah, “Isolation, characterization and neuroprotective activity of foledicitin: an in vivo study,” *Life (Basel)*, vol. 11, no. 8, 2021.
[25] P. Tagde, P. Tagde, F. Islam et al., “The multifaceted role of curcumin in advanced nanocurcumin form in the treatment and management of chronic disorders,” *Molecules*, vol. 26, no. 23, 2021.
[26] K. J. Hupa, K. Stein, R. Schneider et al., “AIM2 inflammasome-derived IL-1β induces postoperative ileus in mice,” *Scientific Reports*, vol. 9, no. 1, p. 10602, 2019.
[27] E. Meroni, N. Stakenborg, M. F. Viola, and G. E. Boeckxstaens, “Intestinal macrophages and their interaction with the enteric nervous system in health and inflammatory bowel disease,” *Acta Physiologica*, vol. 225, no. 1, p. 10602, 2019.
[28] Z. Xiao, C. Wilson, H. L. Robertson et al., “Inflammatory mediators in intra-abdominal sepsis or injury - a scoping review,” *Critical Care*, vol. 19, no. 1, p. 373, 2015.
[29] T.-C. Yang, S.-W. Zhang, L.-N. Sun, H. Wang, and A.-M. Ren, “Magnolol attenuates sepsis-induced gastrointestinal dysmotility in rats by modulating inflammatory mediators,” *World Journal of Gastroenterology*, vol. 14, no. 48, pp. 7353–7360, 2008.

[30] E. E. Martinez, D. Zurakowski, L. Pereira et al., “Interleukin-10 and zonulin are associated with postoperative delayed gastric emptying in critically ill surgical pediatric patients: a prospective pilot study,” *Journal of Parenteral and Enteral Nutrition*, vol. 44, no. 8, pp. 1407–1416, 2020.

[31] M. Kato, I. Honda, H. Suzuki, M. Murakami, S. Matsukawa, and Y. Hashimoto, “Interleukin-10 production during and after upper abdominal surgery,” *Journal of Clinical Anesthesia*, vol. 10, no. 3, pp. 184–188, 1998.

[32] Z. Shuja and H. M. Colecroft, “Regulation of microdomain voltage-gated L-type calcium channels in cardiac health and disease,” *Current Opinion in Physiology*, vol. 2, pp. 13–18, 2018.

[33] M. S. Bari, L. Khandokar, E. Haque et al., “Ethnomedicinal uses, phytochemistry, and biological activities of plants of the genus Gynura,” *Journal of Ethnopharmacology*, vol. 271, Article ID 113834, 2021.

[34] M. M. Rahman, A. S. M. A. Reza, M. A. Khan et al., “Unfolding the apoptotic mechanism of antioxidant enriched-leaves of Tabebuia pallida (lindl.) miers in EAC cells and mouse model,” *Journal of Ethnopharmacology*, vol. 278, Article ID 114297, 2021.

[35] S. Ahmed, H. Khan, M. Aschner, H. Mirzae, E. Küpeli Akkol, and R. Capasso, “Anticancer potential of furanocoumarins: mechanistic and therapeutic aspects,” *International Journal of Molecular Sciences*, vol. 21, no. 16, 2020.

[36] A. E. Kupeli, Y. Genc, B. Karpuz, E. Sobarzo-Sánchez, and R. Capasso, “Coumarins and coumarin-related compounds in pharmacotherapy of cancer,” *Journal of Cancer*, vol. 12, no. 7, 2020.

[37] M.-Y. Wu, E.-J. Wang, D. Feng, M. Li, R. D. Ye, and J.-H. Lu, “Pharmacological insights into autophagy modulation in autoimmune diseases,” *Acta Pharmacutica Sinica B*, vol. 11, no. 11, pp. 3364–3378, 2021.

[38] H. Yuan, Q. Ma, H. Cui et al., “How can synergism of traditional medicines benefit from network pharmacology?” *Molecules*, vol. 22, no. 7, 2017.

[39] S. Mitra, M. S. Lami, A. Ghosh et al., “Hormonal therapy for gynecological cancers: how far has science progressed toward clinical applications?” *Journal of Cancer*, vol. 14, no. 3, 2022.

[40] F. I. Fahad, N. Barua, M. S. Islam et al., “Investigation of the pharmacological properties of lepidagathis hyalina nees through experimental approaches,” *Jewish Life*, vol. 11, no. 3, 2021.